Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study
The Journal of Clinical Endocrinology & Metabolism · 2026
DOI: 10.1210/clinem/dgaf661 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Jennifer L Miller und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, University of Florida College of Medicine, Gainesville, FL 32608, USA. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Hyperphagia, Diazoxide, Choline. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Soleno Therapeutics..
Abstract (Originalsprache)
Context
The hallmark condition of Prader-Willi syndrome, a rare, genetic neurobehavioral/metabolic disorder, is life-threatening hyperphagia.
Objective
We assessed the efficacy and safety of diazoxide choline extended-release (DCCR) tablets for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome.
Methods
We conducted a 16-week, randomized withdrawal study in children and adults with Prader-Willi syndrome and hyperphagia. Participants who previously completed randomized (13-week DCCR or placebo) and open-label (2.5-4.5 years DCCR) studies were randomized 1:1 to receive once-daily DCCR or placebo. The primary endpoint was Hyperphagia Questionnaire for Clinical Trials (HQ-CT) total score change from baseline to 16 weeks. Secondary endpoints included Clinical Global Impression of Severity (CGI-S) and Improvement (CGI-I); exploratory endpoints included weight and body mass index (BMI) z-score.
Results
Seventy-seven participants were randomized (DCCR:38; placebo:39). Statistically significant increases in HQ-CT from baseline to week 16 were observed with placebo vs DCCR [least square (LS) mean (standard error) change 7.6 (1.09)] with placebo and 2.6 (1.12) with DCCR; P = .0022. CGI scores favored DCCR but were not significantly changed. Consistent with the hyperphagia response, the placebo cohort gained more weight and increased their BMI z-score more than the DCCR cohort [LS mean weight difference (95% confidence interval) −1.6 kg (−3.1, −0.1)]; LS mean z-score difference was −0.09 (−0.17, −0.01). Adverse events were similar with both treatments, with no serious adverse events in the DCCR arm.
Conclusion
Continued DCCR treatment was superior to placebo for hyperphagia. DCCR appears to offer meaningful therapeutic benefits for people with Prader-Willi syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Endocrinology, University of Florida College of Medicine, Gainesville, FL 32608, USA.
- Department of Endocrinology, Chelsea and Westminster Hospital, London SW10 9NH, UK.
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Endocrinology, Seattle Children's Hospital, Seattle, WA 98105, USA.
- US Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
- Department of Clinical Genetics, Stanford University, Palo Alto, CA 94305, USA.
ORCID-Profile: Jennifer L Miller, Virginia Kimonis, Evelien Gevers
Förderung
- Soleno Therapeutics.
Zitieren
APA
Miller, J. L., Bridges, N., Felner, E. I., Salehi, P., Yanovski, J. A., Stevenson, D. A., Mejia-Corletto, J., Shaikh, M. G., Abuzzahab, M. J., Fleischman, A., Kimonis, V., Shoemaker, A. H., Holland, A., Bird, L. M., Obrynba, K. S., Lah, M., Littlejohn, E., Harwood, K., Shea, H., …, & Gevers, E. (2026). Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf661
Vancouver
Miller JL, Bridges N, Felner EI, Salehi P, Yanovski JA, Stevenson DA, et al. Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf661
BibTeX
@article{Miller2026,
author = {Miller, Jennifer L and Bridges, Nicola and Felner, Eric I and Salehi, Parisa and Yanovski, Jack A and Stevenson, David A and Mejia-Corletto, Jorge and Shaikh, Mohamad G and Abuzzahab, M Jennifer and Fleischman, Amy and Kimonis, Virginia and Shoemaker, Ashley H and Holland, Anthony and Bird, Lynne M and Obrynba, Kathryn S and Lah, Melissa and Littlejohn, Elizabeth and Harwood, Katerina and Shea, Heidi and Viskochil, David and Hirano, Patricia and Yen, Kristen and Ballal, Shaila and Huang, Michael and Cowen, Neil M and Bhatnagar, Anish and Gevers, Evelien},
title = {Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
doi = {10.1210/clinem/dgaf661}
}
EUVIMED